baxter announc strong fourth-quart result cautiou
increas fve slightli
page full analyst note jan
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research jan
estim jan
price data
rate updat
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
follow spin-off baxalta baxter new
manag team focus increas effici
innov medic product focu result much
improv profit cash flow gener sinc go
forward compani aim roughli organ sale growth
primarili new product geograph launch
double-digit adjust earn per share free cash flow growth
compound annual acquisit could add
prospect
baxter renal acut care technolog support patient
fail organ often kidney segment
compani gener revenu at-hom patient
use periton dialysi pd equip solut
howev also sell hemodialysi product dialysi clinic
continu renal replac therapi crrt organ
support equip intens care unit new renal segment
launch includ kaguya under-penetrated pd market
japan hdx enabl theranova mimic kidney function
close point care pd system greatli reduc solut
ship month acut care baxter plan launch product
like prismax simplifi burden deliv crrt
baxter pursu ambiti growth strategi roughli doubl
number molecul sell varieti deliveri
wound closur bleed control product new launch
faster prep version flagship hemostat floseal could
help clinician save signific time oper room
medic deliveri nutrit manag need turn
around oper recent hurrican regulatori
concern damag baxter reput reliabl supplier
critic therapi effort may take time new
segment return growth
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
busi segment renal segment sale includ
periton dialysi hemodialysi product chronic ill patient
acut therapi segment offer kidney organ support
tool intens care situat medic deliveri segment
sale sell iv pump administr set solut nutrit
sale offer parenter nutrit therapi
pharmaceut segment sale offer inject drug anesthet
gase compound servic advanc surgeri segment
sale provid hemostast product biosurg sealant contract
manufactur round remain sale
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
baxter announc strong fourth-quart result
cautiou increas fve slightli jan
oper result expect strength
top oper profit line given estim cash
flow gener sinc last major valuat updat
rais fair valu estim per share
howev continu view baxter share
overvalu recent trade around see
signific uncertainti around share
fourth-quart full-year result look roughli line
expect baxter highlight gener
billion sale fourth quarter report
basi oper basi oper
margin would previou guidanc
strength help compani report billion
report basi oper
basi similar expect full year
manag outlook fell
expect suspect conservat may
work outlook baxter expect sale
growth expect oper margin
report basi expect
adjust basi baxter plan
invest product capac relat trump
administr plan promot at-hom treatment
increas demand baxter periton dialysi tool may
boost prospect long run uncertainti surround
plan outflow near term also baxter current
conduct intern account investig
delay financi report oper profit
line cash flow basi sinc overal
factor obscur firm near-term free cash flow
gener somewhat creat uncertainti
around baxter valuat opinion although top-lin
rais fair valu estim per share
primarili reflect estim cash flow gener
sinc last updat oper assumpt larg
unchang low-single-digit growth
expect baxter revenu grow compound
annual segment expect renal care
grow compound annual
expect compound annual growth period
baxter medic deliveri segment success
normal growth pattern beyond
recent iv solut headwind pharmaceut
estim baxter ambiti growth plan lead
compound annual growth around
consid on-going headwind may difficult
overcom estim nutrit segment
grow compound annual next five year
new product launch continu domin
respect nich expect acut therapi
advanc surgeri segment lead organ
expect growth respect compound
annual
adjust oper margin
assum baxter reach low
end manag target rang margin
expans come continu sell gener
administr cost control gross margin
expans mix benefit manufactur
effici improv profit effici capit
expenditur plan help baxter gener billion
free cash flow billion
use weight averag cost capit around
discount assumpt assum lower-cost debt
becom slightli preval part capit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
bear-cas scenario valu baxter per share
scenario assum new product launch
lacklust headwind iv solut nutrit
continu keep sale growth next
five year versu expect base case forecast
gross margin improv materi
expect firm adjust oper margin
exceed well target
free cash flow reach billion
baxter dug narrow moat around provid dialysi
inject therapi complex deliveri system
baxter claim top-tier posit product
line typic compet concentr group
peer overal think would difficult new firm
enter nich primarili due switch cost
associ medic equip
intang asset surround proprietari technolog
manufactur process factor form basi
baxter moat gener see long runway
baxter gener econom profit exist
technolog innov pipelin new product
current baxter gener return invest capit
midteen well excess capit cost
firm introduc new technolog aim becom
even effici believ margin could improv
bolster confid baxter abil
gener econom profit long run
renal care segment sale believ
baxter benefit primarili switch cost relat
place equip intang asset associ
second-largest
provid dialysi equip relat consum
behind freseniu medic
organ offer broad spectrum dialysi product
strength larg lie separ technolog
presenc rel stabl healthcar market
give compani medium uncertainti rate
bull-cas scenario valu baxter per share
scenario assum new product launch
favor price condit greater market penetr
boost sale growth
base-cas scenario see potenti
variabl base-cas forecast nutrit
segment higher-growth acut therapi
advanc surgeri segment although segment
contribut higher growth rate bull scenario
cost-sav estim streamlin manufactur
distribut effort success transit
growth factor push adjust oper margin
slightli high end target
rang free cash flow rise billion
scenario
forecast manag exceed
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
geograph footprint periton dialysi
product baxter thrive home set strong
presenc emerg market baxter domin pd
medic product market market share around
versu freseniu patient share altern
freseniu lead way hemodialysi technolog
use clinic hemodialysi
patient share versu baxter around share pd
equip place baxter structur payment use
equip relat consum monthli
subscript consum tube solut
deliv directli patient baxter
logist network opinion treatment
work patient littl incent switch due
inertia factor surround train around
self-administ treatment compani busi
model creat recur revenu stream
consum place equip baxter proprietari
medic technolog pd abil continu
innov creat moat sourc relat intang asset
baxter pd offer current benefit
differenti cycler sharesourc technolog
commun patient result doctor allow
doctor adjust treatment remot
particularli valuabl rural emerg market
factor current set baxter tool apart
competit pd offer abil innov remain core
intang asset moat sourc case
medic
initi includ point care pd system greatli reduc
solut ship month current weigh
pound hdx dialyz enabl theranova
close mimic kidney function aim
reduc cardiovascular side effect often associ
similar dynam renal care busi exist baxter
acut therapi segment sale sell organ
support tool intens care unit hospit baxter
clearli lead continu renal replac therapi
busi believ moat acut therapi stem
primarili switch cost relat caregiv train
intang asset similar renal care segment
rel small percentag baxter total sale
estim midsingl digit percentag sale
baxter
sustain competit advantag recur revenu
outsid renal care infus pump medic
technolog help hospit staff primarili nurs
automat administ medic therapi often lead
recur consum sale administr set iv
solut inject therapi infus pump
rel long life seven year give
long period enjoy recur consum sale
pump place pump offer network
softwar help devic becom embed
workflow caregiv
replac cycl hospit often stick familiar
technolog ensur smooth therapi administr
caregiv well overal infus pump place
hospit believ facil unlik creat
workflow disrupt switch new pump provid
devic often consid gpo contract
negoti on-going sale administr set
therapeut solut although altern deliveri
method util inject therapi -- iv
solut sale nutrit sale
pharmaceut estim sale -- could
infus pump repres key recur
revenu associ infus pump technolog
intang asset front technic featur infus
pump relat consum posit neg
affect caregiv workload patient experi
baxter proprietari technolog remain top-tier
posit concentr market second largest
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
provid also baxter innov pipelin
appear full four new infus pump expect
launch includ new pump platform
includ option larg volum pump syring
administr patient-control analgesia one
pump put baxter par pump
market leader overal infus
pump busi appear add baxter switch cost
intang asset moat sourc rel
concentr market includ former hospira
oper freseniu braun
carefus acquisit
part consum stori infus
pump believ baxter therapeut offer
estim sale -- iv solut estim
baxter sale nutrit sale gener
pharmaceut sale -- contain element
scale-rel advantag intang asset well
although consid cost advantag primari
moat sourc baxter overal baxter enjoy top
posit iv solut stand lead posit
parenter nutrit excel difficult manufactur
gener pharmaceut anesthesia asept
premix baxter typic face limit competit
target market top-tier competitor market
includ freseniu braun former hospira asset
overal see signific
barrier entri around busi keep
inject market baxter particip quit
concentr competit perspect specif
key peer estim would take
million three year build manufactur facil
would allow new entrant gain enough scale
compet effect iv solut busi
 iv solut market serv primarili three
provid baxter icu medic freseniu se
similarli
larg
invest would requir nutrit
gener pharmaceut busi beyond up-front
cost on-going cost associ ensur
complianc due stringent regulatori standard remain
high factor contribut signific entri barrier
new competitor highlight recent
shortag iv solut nutrit market
share shift occur primarili exist
player rather invit signific new competit
beyond scale requir compet success iv
solut nutrit pharmaceut busi see
intang asset relat primarili
provid mix benefit reput
requir consid long-term supplier
hospit nich even gener pharmaceut
baxter primarili particip market complex
manufactur administr requir
inhal anesthet inject therapi franchis
baxter typic face competit
competitor primarili due manufactur complex
much higher oral gener exampl
competit price pressur pervas
beyond gener manufactur requir baxter
also excel asept premix product manufactur
requir keep molecul stabl help ensur
safeti product administr offer ready-to-us
inject care set improv patient safeti
reduc time associ administr task
creat valuabl tool nurs doctor
front line care help baxter gener mix
benefit otherwis commodifi market
nutrit product baxter benefit intang
differenti formul deliveri system ad
intang asset see reputational-rel
therapeut offer well
particularli around abil reliabl supplier
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
ramp invest new molecul gain scale
put level play field larger peer
view posit moat busi
neg iv nutrit solut baxter recent
suffer reput setback hurrican activ
knock manufactur capac
essenti therapi despit longer suppli
constrain baxter still experienc revenu declin
busi hospit custom continu
use supplier lower-pr administr method
requir baxter shortag period baxter
reput reliabl supplier critic therapi
appear weaken may take time
chang reput hospit protocol wake
recent shortag period overal though view
posit trend pharmaceut neg trend
iv nutrit solut larg offset
essenti therapi hospit gpo negoti
advanc surgeri sale think firm benefit
primarili intang asset proprietari
product control bleed close wound
surgic procedur baxter occupi second posit
market behind johnson johnson
advanc hemostat sealant flagship tisseel
floseal product remain differenti baxter continu
innov area new launch aim
includ reduc prepar time floseal reduc
sutur time coupler product on-going
innov add sustain segment
baxter segment sale consist primarili
contract manufactur pharmaceut compani
contribut baxter scale howev
view contract manufactur advantag busi
baxter moat trend appear stabl
busi compani face competit limit
number peer due difficulti compet
medic product switch cost medic
equip scale requir intang asset
target market gener view baxter compet
innov new product launch across busi line
help baxter broaden market offer remain
top-tier competitor obtain mix-rel benefit
factor give us larg stabl view trend
busi despit price constraint common
healthcar industri posit one
price-sensit busi pharmaceut baxter
evolv primarili
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
obaxt new manag team rev
growth engin addit evolutionari
goal major busi line pipelin
includ sever long-term wildcard stock
potenti treat blood-bas cancer
filtrat technolog
oemerg market sale prime
sourc growth mani baxter product
especi periton dialysi nutrit solut
oth compani continu strive even higher
profit keep earn growth
sale growth forese futur
oalthough baxter product essenti medic
care patient health mani similar
altern limit baxter price power
owhil pull trigger larg deal yet
baxter new manag team shown
appetit acquisit add uncertainti
prospect could reduc balanc sheet
obaxt reput reliabl supplier iv
solut nutrit relat market share may
easi recov recent shortag
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
baxter continu oper net leverag significantli
time target net leverag
manag debt come due next five year
fulli cover exist cash also on-going free cash flow
billion manag expect grow
billion billion appear
strong give baxter plenti financi flexibl
substanti financi resourc dispos
firm oper net leverag target think
baxter capac consid capital-alloc
activ caus net leverag rise recent level
exampl manag highlight appetit
acquisit also baxter could return cash
sharehold compani made billion dividend
payment aim return
adjust net incom sharehold go forward
repurchas billion share baxter
repurchas anoth billion first quarter
author repurchas billion march
presenc rel stabl healthcar market
give compani medium uncertainti rate think
baxter shed riskier asset baxalta spin-off
leav well-diversifi compani particip
market limit risk signific disrupt howev
baxter product line particularli iv solut
nutrit product gener inject
commodifi new competitor decid make
substanti invest need enter market
think price pressur manag
volum increas mix benefit differenti
must innov maintain competit advantag
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
compani
particularli renal care infus pump acut therapi
appropri product set peer may surpass
baxter technolog enough affect market share
eventu baxter appetit acquisit also appear
increas creat uncertainti around
trajectori could add financi leverag
balanc sheet factor could add risk
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
ceo/chairman board/
repres date owner name posit common share held report holder issuer
capit research manag compani
share
fund
share
fund
current assign baxter standard stewardship
rate recogn signific out-performance
new manag team deliv sharehold sinc
take split baxalta gener
think baxter asset neglect bit
previou organiz structur busi
qualiti still remain high due inher competit
advantag new manag team strategi
refresh profit
perspect remain baxter busi
split jose almeida previous
chairman ceo covidien prior acquisit
replac longtim baxter chairman ceo
robert parkinson jr sinc join baxter almeida
team focus improv profit cash
flow margin risen substanti baxter
current busi
larg overshadow
higher-growth higher-margin baxalta asset prior
split pleas manag team
abl boost profit line med-tech industri
standard short time would also note
almeida appear rev previous
rel dormant innov engin bode well
growth prospect
although view chang posit signific
uncertainti surround new team capit alloc
polici remain concern potenti acquisit
could eras profit gain manag
made past year would also note
team shi repurchas share
recent quarter gener glad see
manag attempt purchas share attract
valuat remain seen team maintain
disciplin face share appreci sinc earli
push stock fair valu
opinion sharehold also awar financi
flexibl could declin pull trigger larg
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
acquisit current believ baxter capac
consid activ increas net leverag
would want see firm add much leverag beyond
net leverag target time sustain period
given innov regulatori risk associ
target market strong growth prospect
surpris baxter current dividend pay-out ratio
remain target around adjust net
incom growth prospect slow increas
pay-out ratio could add sharehold return well
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
baxter announc strong fourth-quart result
cautiou increas fve slightli jan
oper result expect strength
top oper profit line given estim cash
flow gener sinc last major valuat updat
rais fair valu estim per share
howev continu view baxter share
overvalu recent trade around see
signific uncertainti around share
fourth-quart full-year result look roughli line
expect baxter highlight gener
billion sale fourth quarter report
basi oper basi oper
margin would previou guidanc
strength help compani report billion
report basi oper
basi similar expect full year
manag outlook fell
expect suspect conservat may
work outlook baxter expect sale
growth expect oper margin
report basi expect
adjust basi baxter plan
invest product capac relat trump
administr plan promot at-hom treatment
increas demand baxter periton dialysi tool may
boost prospect long run uncertainti surround
plan outflow near term also baxter current
conduct intern account investig
delay financi report oper profit
line cash flow basi sinc overal
factor obscur firm near-term free cash flow
gener somewhat creat uncertainti
around baxter valuat opinion although top-lin
result roughli met expect report
metric howev compani report signific
figur earn per share firm launch
intern investig report foreign currency-
relat item suspect ultim result
inquiri manag given limit magnitud
transact investig stock fallen
earli trade alreadi view baxter share
overvalu anticip chang fair valu
estim base announc
quarter baxter sale grew oper
billion line manag previou
expect report basi segment renal
benefit on-going growth patient serv
quarter off-set somewhat discontinu
hemodialysi product set temporari suppli constraint
revaclear dialyz acut therapi perform well
quarter help launch next gener
prismax system support kidney failur patient
acut care set momentum continu medic
deliveri clinic nutrit seen
improv hurricane-rel issu caus
suppli shortag custom switch advanc
surgeri also turn strong result help competit
bottom line baxter report give outlook
figur oper profit line due on-going
account investig pleas see
adjust oper margin grow quarter
basi point report prior-year
period sinc compani report earn per
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
flow gener near term opinion given
share yet remain unclear baxter perform
metric even adjust basi gener would
expect one quarter profit chang view baxter
intern account investig appear focus
way baxter account foreign currenc gain
loss sever prior period import
probabl would chang view firm exampl
baxter reveal net foreign exchang gain amount
million million million million
million million year
first half respect
subject investig ultim charg
could larger smaller figur view
firm free cash flow gener probabl would
chang significantli initi estim appear
accur file perspect though compani
expect turn third-quart result
sec time manner like amend previou
file investig complet total
factor obscur firm recent free cash flow gener
somewhat creat uncertainti around baxter
trump administr
compani also would comment specif
expect manag appear somewhat
cautiou given previous announc plan invest
product capac at-hom dialysi equip
advanc american kidney health initi top
periton dialysi pd provid world expect
baxter key beneficiari expans at-hom
therapi unit state given technolog
physician relationship advantag field
increas demand compani pd tool may boost
prospect especi outer year forecast
period uncertainti surround cumul free cash
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
